8-KOther Events

Edwards Lifesciences Corp 8-K Report (Jul 27, 2004)

Filed July 27, 2004For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corporation, dated July 27, 2004, primarily serves to announce the company's financial results for the second quarter of 2004. The core information is contained within the attached press release (Exhibit 99.1), which details the company's performance during the quarter. While the filing itself is brief, it directs investors to the press release for substantive financial details, including revenue, earnings, and potentially other key performance indicators relevant to the medical device sector. Investors should review the attached press release to understand the company's operational and financial standing as of that reporting period. The filing specifies that certain portions of the press release (the first two paragraphs and pages 7-13) are considered "filed" under the Securities Exchange Act of 1934, making them subject to SEC scrutiny. The remainder of the press release is furnished, meaning it's provided for informational purposes but not subject to the same level of liability. This distinction is important for understanding the legal implications of the disclosed information.

Key Highlights

  • 1Edwards Lifesciences Corporation filed an 8-K on July 27, 2004.
  • 2The primary purpose of the filing is to disclose the company's financial results for the second quarter of 2004.
  • 3The detailed financial results are provided in an attached press release (Exhibit 99.1).
  • 4Specific sections of the press release are designated as 'filed' under the Exchange Act, while others are 'furnished'.
  • 5Investors are directed to the press release for comprehensive financial and operational performance data for Q2 2004.
  • 6The filing provides the company's principal executive office address and contact information.
  • 7Bruce P. Garren, Corporate Vice President, General Counsel and Secretary, signed the report on behalf of the company.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and disseminate Edwards Lifesciences Corporation's financial results for the second quarter of 2004 to the public and the SEC. The detailed financial information is provided in an accompanying press release.

The specific financial details for the second quarter of 2004 are contained within Exhibit 99.1, which is a press release dated July 27, 2004, attached to this 8-K filing. Investors should refer to this press release for comprehensive data.

When information is 'filed' under the Exchange Act, it is subject to specific liability provisions, meaning the company and its officers can be held accountable for any misstatements or omissions. 'Furnished' information is provided for disclosure purposes but generally does not carry the same level of legal liability.

Based on the provided text, this 8-K filing is solely focused on disclosing the second quarter 2004 financial results. Any other material developments would need to be found in other sections of the filing or separate disclosures, but this specific report highlights the financial performance announcement as the key event.